

PRESS RELEASE

Cordlife Honoured As One Of Forbes Asia's “Best Under a Billion” Companies

Singapore, 4 November 2015 – Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”), a mother and child consumer healthcare company, announced today that it was honoured by Forbes Asia as one of the “Best Under a Billion” companies at an awards ceremony and dinner held at Sunway Resort Hotel and Spa, in Kuala Lumpur, Malaysia on 2 November 2015.

The event and the awards ceremony paid tribute to the entrepreneurial success of the 200 companies that made Forbes Asia's list of being the best small and mid-sized public companies in Asia. The Group was chosen from an universe of approximately 17,000 eligible companies with annual revenues between US\$5 million and US\$1 billion and positive net income, based on sales and earnings growth in the past 12 months and three-year periods, and five-year return on equity. The Group's Chief Executive Officer, Mr Jeremy Yee also participated in a panel discussion moderated by Tim Ferguson, Editor of Forbes Asia, titled “Blueprint for growth” prior to the awards ceremony, where he shared his insights on heading an emerging company and bringing it to the next level.

Mr Jeremy Yee, Executive Director and Chief Executive Officer of Cordlife said: “We are deeply honoured to be selected by Forbes Asia as one of the “Best Under a Billion” companies. This represents a strong endorsement of our strategies and efforts to grow the Company, which has delivered a respectable two-year revenue CAGR of 28.8%. Moving forward, we seek to maintain our leading market positions in the Asian cord blood and cord lining banking markets and innovate with new healthcare products and services in the mother and child segment. Growing demand for healthcare services and products in the region coupled with our long term track record should position us well for the next phase of growth.”

- The End -

ABOUT CORDLIFE GROUP LIMITED (Bloomberg stock code: CLGL)

Incorporated in May 2001, Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”), is a consumer healthcare company catering to the mother and child segment and a leading cord blood and umbilical cord lining banking services provider. Amongst the first private cord blood banks in Asia, Cordlife has the largest market share of private cord blood banks in Singapore, Indonesia and the Philippines¹. In Hong Kong and India, it is amongst the top three market leaders for private cord blood banks.

Cordlife, through its collaborative relationships and arrangements with major private hospitals and clinics such as Thomson Medical and Parkway East Hospital, has continued to increase public awareness of its cord blood banking service in Singapore. Overseas, Cordlife also acquired a 19.92% stake in October 2013, which was subsequently increased to approximately 31.81% in December 2013, in StemLife Berhad (“StemLife”). StemLife is a fully licensed cord blood banking facility with the Ministry of Health Malaysia currently listed on the ACE Market of Bursa Malaysia.

Cordlife has been accredited since 2005 by AABB (formerly known as the American Association of Blood Banks), an association involved in the field of transfusion medicine and cellular therapies. The Group is one of the first private cord blood banks in Singapore and amongst the first in Hong Kong to have released cord blood units for transplants and other therapeutic use. In Singapore, Cordlife was the first private cord blood bank to release cord blood units for the treatment of cerebral palsy. In addition, in April 2013, Cordlife became the first private cord blood bank in Asia to have launched SEPAX^{®2}, a Swiss-made FDA-approved, GMP compliant automated stem cell processing system that maximises automation while ensuring consistently high cell recoveries. Cordlife also has a strategic alliance with CordLabs Asia Pte. Ltd., a wholly-owned subsidiary of CellResearch Corporation Pte. Ltd., which gives the Group the exclusive rights to market their technology in relation to the provision of human postnatal umbilical cord lining storage services and training and the transfer of the know-how, in India, Indonesia, Malaysia, Philippines, Singapore, Hong Kong and Thailand.

Cordlife’s track record has won the Group many accolades and awards, including: Best Medical Service Award 2010 by Capital CEO Supreme Brand Awards; Top Pregnant/Baby Products Award 2011 by Pregnancy Magazine; Outstanding Financial Strength Cord Blood Bank 2012 by Quamnet Outstanding Enterprise Awards; Most Popular Brand Award 2010 – The Most Popular Cord Blood Bank by TVB Weekly; U-Choice Lifestyle Brand Award 2010 by Metroinfo FM99.7; Baby & Kid Brands Awards Year 2013, “My Favourite Cord Blood Bank” by Hong Kong Economic Times; 2014 Most Popular Stem Cell Bank Reader’s Choice by Child Magazine; 2013-2014 MyBB Parent-Child Favorite Cord Blood and Umbilical Cord Bank Company and Baby Kingdom Top 10 Family Brand Award 2012². In October 2012, Cordlife was awarded the prestigious SIAS Investors’ Choice Awards as runner-up in the “Most Transparent Company Award 2012” New Issues Category. In August 2013, we were presented with Merit Award for the Singapore Corporate Awards 2013, “Best Investor Relations Award”. In November 2013, Cordlife was named the “Most Transparent Company 2013” in the Retail & Household Goods Category and Mainboard Small Caps Category at the 14th SIAS Investors’ Choice Awards. In October 2015, named as the Runner-up of the 16th SIAS Investors’ Choice Award, Singapore Corporate Governance Award (SCGA) 2015, Mid and Small Category. Cordlife was also honoured by Forbes Asia

¹Source : Deloitte & Touche Financial Advisory Services Limited report, October 2014

²Awarded to Cordlife (Hong Kong) Limited



as one of the “Best Under a Billion” companies at an awards ceremony and dinner held in November 2015.

ISSUED ON BEHALF OF : Cordlife Group Limited
BY : Financial PR Pte Ltd
4 Robinson Road #04-01
The House of Eden
Singapore 048543

CONTACT : Mr Kamal Samuel / Mr Mark Lin
OFFICE : 6438-2990
EMAIL : kamal@financialpr.com.sg / marklin@financialpr.com.sg
